09:48 AM EST - BELLUS Health Inc. : Today announced that it will convene a Key Opinion Leader meeting to discuss chronic cough on Tuesday, July 16, in New York City. The event will include discussions on the unmet medical need in the category, and a review of current therapies in development including P2X3 antagonists. BELLUS Health will also provide clinical and regulatory updates on its lead P2X3 antagonist product candidate for the treatment of chronic cough, BLU-5937. BELLUS Health Inc.
shares T.BLU are trading up $0.03 at $2.96.
